Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.22% is 211% above its 5-year average of -80.24%, near the high end of its 5-year range (-49885.37%–100.00%).
96.69% above its 12-month average of 45.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
89.22%
GROSS MARGIN AVG TTM
45.36%
GROSS MARGIN AVG 3Y
95.74%
GROSS MARGIN AVG 5Y
-80.24%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.69%
CURRENT VS 3Y AVG
-6.81%
CURRENT VS 5Y AVG
+211.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+115.61%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$111.85M
Gross Margin
89.22%
TTM Avg
45.36%
3Y Avg
95.74%
5Y Avg
-80.24%
Market Cap
$111.40M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$112.81M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$110.41M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$110.12M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$114.34M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$114.27M
Gross Margin
-60.26%
TTM Avg
-75.23%
3Y Avg
-314.56%
5Y Avg
-212.54%
Market Cap
$114.35M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $111.85M | 89.22% | 45.36% | 95.74% | -80.24% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $111.40M | 11.17% | 22.02% | 17.41% | 13.61% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | 0.00% | 0.00% | 50.00% | 33.33% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.41M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apyx Medical Corporation (APYX)vs › | $110.12M | 33.94% | 48.53% | 56.75% | 59.91% |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.34M | 67.34% | 64.03% | 72.89% | 33.80% |
| MaxCyte, Inc. (MXCT)vs › | $114.14M | 79.43% | 81.39% | 84.94% | 86.41% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.27M | -60.26% | -75.23% | -314.56% | -212.54% |
| Genelux Corporation (GNLX)vs › | $114.35M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.90M | 46.49% | 23.25% | 11.62% | 7.75% |
Gross Margin
89.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 92.72% |
| 2025-12-31 | 91.33% |
| 2025-09-30 | -145.33% |
| 2025-06-30 | 88.09% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 85.23% |
| 2023-09-30 | -50.19% |
| 2023-06-30 | -422.38% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | -574.19% |
| 2022-09-30 | -305.91% |
| 2022-06-30 | -478.49% |
| 2022-03-31 | -525.20% |
| 2021-12-31 | -3050.49% |
| 2021-09-30 | -49885.37% |
| 2021-06-30 | -6581.72% |
| 2021-03-31 | -6447.55% |
| 2020-12-31 | -124.30% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
